Vivalis and Innate Pharma sign a collaboration and commercial license agreementCollaboration and Commercial License Agreement • April 29th, 2021
Contract Type FiledApril 29th, 2021Vivalis and Innate Pharma sign a collaboration and commercial license agreement to develop Innate's novel monoclonal antibody, to be manufactured with Vivalis' EB66® platform, for rare cutaneous cancers.